First studies underway at Mayday University Hospital!

Posted:
16
June 2005

We are delighted to have started conducting clinical trials within Mayday University Hospital's flagship facilities. Construction and development of the new purpose built units was completed in May, allowing Early Phase studies to commence and complement our other premises within St George's University London.

“We moved into our new premises in early May and we are now conducting clinical research within the Mayday units. The transition has been very smooth and we are already reaping the rewards of the enhanced set-up.”— Dr Jörg Täubel, Managing Director, Richmond Pharmacology.
“Running clinical trials in our Mayday unit is proving very advantageous. The additional capacity we can manage up to 100 in-patients simultaneously. Our facilities are designed specifically for client and panel requirements and this helps trial conduct to run efficiently. For example, we now have dedicated monitoring facilities on the ward, with adjoining offices for a variety of support functions. I'm looking forward to taking full advantage of these facilities.”— Jean Van Wyk, Senior Research Physician and Head of Medical Department.
“The facilities have been purpose built, and this provides a tremendous advantage for our volunteers. The wards and recreational areas are spacious and comfortable. Volunteer feedback on the internet and lounge rooms has been very favourable. And, of course, it's reassuring to work within the acute environment of the NHS Trust.”— Dr Ulrike Lorch, Medical Director.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more